Frequently Asked Questions
The market is segmented based on , By Drug Type (Biological, Non-Biological), Disease Type (Oncologic Diseases, Metabolic Disease, Hematologic And Immunologic Diseases, Infectious Diseases, Neurological Diseases, Others), Indication Type (Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Cystic Fibrosis, Glioma, Pancreatic Cancer, Ovarian Cancer, Multiple Myeloma, Duchenne Muscular Dystrophy, Renal Cell Carcinoma, Graft Vs Host Disease, Others), Drug Type (Revlimid, Rituxan, Opdivo, Keytruda, Imbruvica, Soliris, Jakaf, Pomalyst, Darzalex, Spinraza, Adcetris), Sale (Generics, Prescribed), Therapy Class (Oncology, Blood, Central Nervous Systems, Endocrine, Cardiovascular, Respiratory), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Sales, Others) – Industry Trends and Forecast to 2030.
.
The Global Orphan Drugs Market size was valued at USD 174.11 USD Billion in 2022.
The Global Orphan Drugs Market is projected to grow at a CAGR of 9.5% during the forecast period of 2023 to 2030.
The major players operating in the market include , F. Hoffmann,La Roche , Novartis AG , Pfizer , Eli Lilly and Company , Johnson & Johnson Services , Merck KGaA , Novo Nordisk A/S , Bristol,Myers Squibb Company , Alexion Pharmaceuticals , Kyowa Kirin Co. , Amgen , Biogen , Celldex Therapeutics , GSK plc. , Eisai Co. , Takeda Pharmaceutical Company Limited , Vertex Pharmaceuticals ,orporated ,.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
